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Abstract
Background: The WHO Model List of Essential Medicines for Children (EMLc) covers medicines for globally
high-burden diseases. Regulatory approval in high-income countries ensures evidence and dosage form but
usually focuses on diseases common in those countries and not in low- and middle-income countries.
Methods: This cross-sectional study assessed supporting evidence for the 346 medicines in the 5th WHO EMLc
and their approval data from the United States, United Kingdom, and Japan.
Results: Of the 346 EMLc medicines, 307 were approved in one or more of the three countries, 278 of which had
supporting evidence of efficacy. The percentage of medicines approved in one or more of the three countries
was lowest for antiparasitics (60%) whereas 100% for medicines for cancers and musculoskeletal and respiratory
conditions were approved. Five of the 30 EMLc antineoplastics had no supporting paediatric evidence. Of the 39
EMLc medicines unapproved in all three countries, 26 were indicated for neglected infectious diseases (NIDs).
Ten of the 26 had supporting paediatric evidence. Seventeen of the 39 unapproved medicines had no paediatric
dosage form available, and all 17 were indicated for NIDs.
Conclusions: Most EMLc medicines for diseases common in the three countries had supporting evidence, which
was closely associated with approval, whereas a substantial number of medicines for NIDs were unapproved in
the three countries, regardless of whether they had supporting evidence. Because of the limited contribution to
the EMLc from high income countries, appropriate incentive mechanisms for pharmaceutical companies are required
to make paediatric development for NIDs feasible and effective.
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Background
The lack of authorised medicines for children has been
an issue of global concern [1–4]. Pharmaceutical com-
panies have been reluctant to invest in developing spe-
cific treatments or adapting existing medicines to meet
the needs of the paediatric population, mainly because
the market is small and therefore of lower commercial
interest. The lack of paediatric development raises the
ethical concern that children have not benefitted from
therapeutic options to the same extent as adults [5, 6].
Age-appropriate dosage forms represent another obs-
tacle in paediatric medication. The absence of an ap-
propriate dosage form for children often results in
suboptimal compliance with recommended drug regi-
mens and undermines efficacy or safety [7]. World
Health Assembly resolution 60.20 urges member states
to take steps to identify age-appropriate paediatric dos-
age forms that are less expensive to produce, more heat
stable, and more convenient to transport than traditional
ones [8]. There are few financial incentives, however, for
pharmaceutical companies to provide paediatric dosage
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forms with relevant evidence of efficacy, safety, and toler-
ability [9].
The World Health Organization (WHO) Model List of
Essential Medicines for Children (EMLc) [10] provides a
priority list of medicines for paediatric health care needs.
Revision and updating of the EMLc by the WHO Expert
Committee on the Selection and Use of Essential Medi-
cines [11] requires evaluation of the scientific evidence,
based on the comparative effectiveness, safety, cost-
effectiveness, and public health need of the medicines.
The Committee’s additions to the EMLc are expected to
support efforts to reduce the cost of EMLc medicines, as
in the case of antiretrovirals [12]. Whereas evidence-
based recommendation is essential for regulatory ap-
proval in high-income countries (HICs), robust evidence
is often unavailable for high-burden conditions such as
neglected infectious diseases (NIDs) [13] prevalent in
low- and middle-income countries (LMICs). Reviewing
applications for the EMLc is challenging because the
Committee must often make decisions to ensure access
to indispensable treatment in the absence of evidence.
This is the reason WHO uses the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) approach [14] to make recommendations for
medicine use in areas where there is a lack of evidence.
Compared with reviews in EMLc, clinical trials to pro-
vide evidence are essential for regulatory approval of
medicines for children in HICs. Development and regu-
lation of medicines are coordinated among International
Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human
Use (ICH) countries, all of which are HICs. The ICH
Tripartite Guideline [15] stipulates conditions for paedi-
atric medicinal product development. ICH regulatory
authorities, the United States Food and Drug Adminis-
tration (FDA), the European Medicines Agency, and the
Pharmaceutical and Medical Devices Agency (PMDA),
all review the clinical trial data. Considerable attention is
paid to internal validity, safety, efficacy, and manufactur-
ing, and focus on the risk-benefit profile of a product.
Subsequent drug approval is independent of the public
health perspective and the cost of the medicine.
HICs have not directly improved access to the EMLc
medicines [1] and may even exploit children in LMICs
[16, 17] to establish evidence. For example, in a clinical
trial involving premature babies with respiratory distress
syndrome that was led by a company from the United
States (US), some participants were to be given a pla-
cebo despite the availability of drugs for the condition
[17]. However, HICs can contribute to the EMLc in co-
operation with the WHO. The paediatric medicine ini-
tiatives of HICs [18] have established and expanded
networks with specific expertise in performing clinical
trials and have improved the scientific evidence and
availability of paediatric dosage forms. These data have
helped the Committee [11] to review and update the
EMLc.
The aim of the present study was to investigate the
implications of approval in HICs and supporting evi-
dence of efficacy for the EMLc medicines. For this pur-
pose, we analysed the evidence and approval status of
EMLc medicines in the US, United Kingdom (UK), and
Japan, which are all members of the ICH.
Methods
Definition of approval status and analysis of approved
products
This study included medicines appearing on the 5th
EMLc [10]. We identified labels available in July 2015
from the DailyMed [19] and Drugs@FDA websites [20]
for US Structured Product Labels, the electronic Medi-
cines Compendium [21] and the Medicines and Health-
care Products Regulatory Agency websites [22] for UK
Summaries of Product Characteristics, and the website
of the PMDA [23] for Japanese labels. We selected these
countries for our comparison because of the similarities
in their drug regulations, as all three are members of the
ICH. The UK provides a good comparison with the US
and Japan because it shares a common language with
the US and provides universal pharmaceutical coverage,
as does Japan.
When the product label covered the indication, dos-
age, and route of administration for children at any age,
the label was considered to be approved for paediatric
use [24]. If a medicine had been discontinued as a pre-
scription drug but was available as an over-the-counter
drug for children, we designated it as approved. In
addition to the paediatric approval status, we also
checked the dosage form on the label to determine
whether it covered any of the paediatric dosage forms on
the WHO list. When we found any paediatric dosage
form available in at least one of the three countries, we
considered the paediatric dosage form to be available.
To enable data from the current study to be used for
comparison in future studies, we analysed the data ac-
cording to the Anatomical Therapeutic Chemical (ATC)
Classification System [25], which classifies drugs by the
organ or system on which they act and their therapeutic,
pharmacological, and chemical properties.
Definition of supporting evidence and analysis of
evidence
To evaluate the supporting evidence for each medicine,
we used the DRUGDEX® System (Truven Health Analytics,
Ann Arbor, MI, USA) [26], which is recognised by the
Centers for Medicare and Medicaid Services as a pharma-
ceutical compendium that describes the efficacy and scien-
tific documentation for prescription drugs and has been
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used to approve payment. When the efficacy of a medicine
was described as “Effective” or “Evidence favors efficacy”
on DRUGDEX, we considered that supporting evidence
was available for the indication. When the therapeutic use
was indicated as “See Drug Consult reference” and the dos-
age and route of administration for children were specified
in the reference, we considered that supporting evidence
was available for the medicine. When the efficacy of a
medicine was described as “Evidence is inconclusive” or
“Ineffective”, we considered that supporting evidence was
not available for the indication. When a medicine or its
evidence was not listed on DRUGDEX, we designated it as
“No evidence”.
Results
There were a total of 346 medicines on the 5th EMLc
(see Additional file 1). Table 1 shows that approval status
in the three countries is closely related to evidence of
efficacy. Supporting evidence was provided for 287
(91%) of the 307 medicines approved in the US, UK or
Japan whereas evidence was available for only 13 (33%) of
the 39 medicines unapproved in in the three countries.
There were 29 medicines approved in one or more of
the three countries without supporting paediatric evi-
dence. These medicines are classified in Table 2 according
to supporting evidence in children and adults. Of the 29
medicines, 26 had supporting evidence in adults.
In Japan, 162 (47%) of the 346 EMLc medicines were
unapproved for children whereas 78 (22%) and 66 (19%)
were unapproved in the US and UK, respectively
(Table 3). Less than half of the 346 EMLc medicines
(160; 46%) were approved in all three countries whereas
307 (89%) were approved in at least one of the three
countries.
Table 4 shows the number of medicines according to
approval status and ATC code. Anti-infectives (code J)
were most represented (99/346; 29%), followed by anti-
parasitics (code P) (40/346; 12%). Antiretrovirals in-
cluded in anti-infectives and itemized in Additional file
1 (Nos.113–126) were all approved in one or more of
the three countries. The percentage of medicines ap-
proved in one or more of the three countries was lowest
for antiparasitics (24/40; 60%) whereas it was 100% for
antineoplastics and medicines for musculoskeletal and
respiratory systems. Of the 30 antineoplastics listed in
Table 4 and itemized in Additional file 1 (Nos.168–197),
only eight, including three corticosteroids and two sup-
portive care agents, were categorised as effective whereas
five cytotoxic agents (bleomycin, cisplatin, etoposide, ifos-
famide, and vinblastine) were categorised as no evidence.
There were 39 medicines unapproved for use in chil-
dren in all three countries. Of these, 26 were indicated
for NIDs. Table 5 shows the 39 medicines classified ac-
cording to supporting evidence in children or adults. Of
these, there was supporting paediatric evidence for 13
(Table 6) but inconclusive or no evidence for 26 medi-
cines. Of the 13 with supporting paediatric evidence but
unapproved in the three countries, 10 were indicated for
NIDs (Table 6). Of the 26 without paediatric evidence,
there was supporting evidence for use in adults for 17
Table 1 Relationship between approval status and evidence of essential medicines for children
Paediatric approval Total Evidence Supporting
evidence rateSupporting Inconclusive Ineffective No evidence
US/UK/Japan 160 155 2 0 3 97%
Two of the three 105 96 0 0 9 91%
One of the three 42 27 2 1 12 64%
None 39 13 4 0 22 33%
Total 346 291 8 1 46 84%
Table 2 Number of essential medicines for children approved
without paediatric evidence in the US, UK, or Japan, in groups








Inconclusive 3 0 1 4
Ineffective 0 0 1 1
No
evidence
23 0 1 24
Total
number
26 0 3 29
Table 3 Approval status of essential medicines for children in
the US, UK, and Japan
Approval status US (%) UK (%) Japan (%)
Approved for both adults
and children
261 (75) 275 (79) 180 (52)
Approved for children only 7 (2.0) 5 (1.4) 4 (1.2)
Unapproved for children 42 (12) 15 (4.3) 87 (25)
Unapproved for both adults
and children
36 (10) 51 (15) 75 (22)
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medicines (Table 7). The therapeutic uses for these 17
include NIDs and rare diseases in children, e.g., coagula-
tion factor deficiency, mydriasis induction in cataract
surgery, and ethylene glycol toxicity. Nine medicines
unapproved in all three countries had no supporting
evidence in either adults or children (Table 8). Eight of
these nine medicines, excluding morphine for sedation,
were indicated for NIDs.
Regarding the availability of a paediatric dosage form
for the 39 medicines unapproved for children in all
three countries, 17 had no paediatric dosage form
(Table 9). All 17 of these were indicated for NIDs. Of
these 17 medicines, 12 had no supporting evidence in
children.
Discussion
This study revealed that most of the EMLc medicines
for diseases common in HICs had supporting evidence
that was closely associated with approval in the three
countries whereas medicines for diseases prevalent in
LMICs but not in HICs were on the list as essential even
though they were unapproved in the three countries or
had no supporting evidence.
Although regulation of medicines is basically harmo-
nised among the US, UK, and Japan, which are all
members of the ICH, we found that the approval gaps
between the US and Japan and between the UK and
Japan were much larger than that between the US and
the UK. Another study reported similar gaps between
the US and Japan in medicines for adults [27]. The
unique requirement of domestic dose-finding studies
[28] has likely resulted in delays in filing applications
for new medicines of non-Japanese origin, which subse-
quently created the gap for paediatric approval in Japan.
Extrapolation of adult data for paediatric approval, if
possible, would help to close this gap. However, the
ICH E11 guideline for clinical trials in the paediatric
population [15] stipulates that pharmacokinetic studies
should generally be performed to support development
of dosage forms and determine pharmacokinetic pa-
rameters in different age groups, so as to support dos-
ing recommendations.
Paediatric medicine initiatives in the US and European
Union (EU) have aimed to improve the availability of
medicines for children [18]. In contrast with the US and
EU, no comprehensive legislation exists in Japan to
provide incentives and facilitate paediatric development.
Although Japan has enhanced its contribution to inter-
national harmonisation through the ICH and has
followed the US and EU by enacting its own paediatric
medicine initiatives, the progress of these regulatory re-
forms has been modest [18, 29].
The approval status of EMLc medicines in the three
countries varied depending upon therapeutic area.
Medicines for diseases common in HICs, e.g., HIV in-
fection, respiratory diseases and cancers, were all ap-
proved in one or more of the three countries. Although
all 30 antineoplastics were approved, their evidence was
not always robust; five cytotoxic agents were cate-
gorised as having no evidence. This means that when
Table 4 Number of essential medicines for children according to approval status, evidence, and Anatomical Therapeutic Chemical
(ATC) code
ATC codea A B C D H J L M N P R S V Total
Approvedb 31 19 11 23 19 99 30 6 32 40 8 11 17 346
Unapprovedc 1 1 1 1 2 10 0 0 3 16 0 1 3 39
Rate of unapproved (%) 3.2 5.3 9.1 4.3 11 10 0 0 9.4 40 0 9.1 18 11
aAnatomical Therapeutic Chemical (ATC) classification codes. A, alimentary tract and metabolism; B, blood and blood-forming organs; C, cardiovascular system; D,
dermatologicals; G, genitourinary system and sex hormones; H, systemic hormonal preparations, excluding sex hormones; J, general anti-infectives for systemic
use; L, antineoplastic and immunomodulating agents; M, musculoskeletal system; N, nervous system; P, antiparasitic products; R, respiratory system; S, sensory
organs; V, various
bEssential medicines for children approved in the US, UK, or Japan
cEssential medicines for children unapproved in the US, UK, and Japan
Table 5 Number of essential medicines for children unapproved in the US, UK, and Japan, classified according to supporting
evidence in children or adults
Evidence in adults
Supporting Inconclusive No evidence Total number
Evidence in children Supporting 12 1 0 13
Inconclusive 3 1 0 4
No evidence 14 3 5 22
Total number 29 5 5 39
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reviewing antineoplastics, regulatory authorities in
these three countries might give priority to effectiveness
rather than to efficacy. The recent proposal of the WHO
Expert Committee’s 2015 meeting with respect to antineo-
plastics [12] opened up the doors to rigorous evidence re-
quirements for other categories of medicines.
Among the 39 medicines unapproved in all three
countries studied, there were differences in the gradient
of supporting evidence and in the availability of a
paediatric dosage form. Although evidence is essential
for regulatory approval in HICs, medicines with good
evidence do not always receive approval. Of the 39
Table 6 Essential medicines for children unapproved in the US, UK, and Japan with paediatric evidence
Name ATCa Therapeutic use Adult efficacyb Paediatric efficacyb Dosage formc
Potassium iodide D Cutaneous sporotrichosis Favours efficacy Favours efficacy A
Doxycycline J Malaria Favours efficacy Favours efficacy A
Amikacin J Tuberculosis Favours efficacy Favours efficacy A
Rifampicin J Leprosy Favours efficacy Favours efficacy A
Capreomycin J Tuberculosis Effective Favours efficacy A
Diphtheria antitoxin J Diphtheria Effective Effective NA
Isoflurane N General anaesthesia Effective Effective A
Primaquine P Malaria Favours efficacy Favours efficacy A
Artesunate P Malaria Effective Effective NA
Artesunate + Mefloquine P Malaria Effective Effective NA
Artesunate + Amodiaquine P Malaria Effective Effective NA
Benznidazole P American trypanosomiasis Inconclusive Favours efficacy NA
Protamine sulfate V Heparin overdose Effective Favours efficacy A
aAnatomical Therapeutic Chemical (ATC) classification codes: D, dermatologicals; J, general anti-infectives for systemic use; L, antineoplastic and immunomodulating
agents; N, nervous system; P, antiparasitic products; V, various
bAdult or paediatric efficacy: Inconclusive, evidence is inconclusive; Favours efficacy, evidence favours efficacy
cDosage Form: A, available; NA, not available
Table 7 Essential medicines for children unapproved in the US, UK, and Japan with supporting evidence in adults but not in
children
Name ATCa Therapeutic use Adult efficacyb Paediatric efficacyb Dosage formc
Fresh-frozen plasma B Coagulation factor deficiency Effective No evidence A
Dopamine C Heart failure Effective No evidence A
Fludrocortisone H Adrenal insufficiency Effective No evidence A
Lugol’s solution H Thyroid storm Effective No evidence A
Levofloxacin J Tuberculosis Favours efficacy No evidence A
Amphotericin B J Leishmaniasis Effective No evidence A
Clofazimine J Leprosy Effective No evidence A
Ribavirin J Viral haemorrhagic fevers Favours efficacy No evidence A
Amitriptyline N Pain in palliative care Effective Inconclusive A
Sodium stibogluconate P Leishmaniasis Favours efficacy No evidence NA
Melarsoprol P African trypanosomiasis Favours efficacy No evidence NA
Suramin sodium P African trypanosomiasis Favours efficacy No evidence NA
Eflornithine P African trypanosomiasis Effective No evidence NA
Triclabendazole P Infection by Paragonimus Favours efficacy Inconclusive NA
Epinephrine (Adrenaline) S Mydriasis induction in cataract surgery Favours efficacy No evidence A
Fomepizole V Ethylene glycol toxicity Effective Inconclusive A
Mesna V Prophylaxis of ifosfamide-induced haemorrhagic cystitis Effective No evidence A
aAnatomical Therapeutic Chemical (ATC) classification code: B, blood and blood-forming organs; C, cardiovascular system; H, systemic hormonal preparations,
excluding sex hormones; J, general anti-infectives for systemic use; N, nervous system; P, antiparasitic products; S, sensory organs; V, various
bAdult or paediatric efficacy: Inconclusive, evidence is inconclusive; Favours efficacy, evidence favours efficacy
cDosage Form: A, available; NA, not available
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medicines, 13 with supporting evidence were for dis-
eases rare among children in HICs; 10 of the 13 were
for NIDs. Because of the small market and low financial
interest, there are few financial incentives for pharma-
ceutical companies to seek approval for the 13 medi-
cines with supporting evidence in children. Although
paediatric dosage forms are unavailable in the US, UK,
and Japan for five of these 13 medicines, appropriate
dosage forms may be available in another country or
could be developed via options other than full develop-
ment [30, 31].
Of the other 26 medicines unapproved in all three
countries without supporting paediatric evidence, 17 had
evidence in adults. The lack of paediatric evidence likely
results from limited numbers of study participants,
probably because the prevalence of most indications for
the 17 medicines is very low in HICs. The need for
separate paediatric development may be reduced by
Table 8 Essential medicines for children unapproved in the US, UK, and Japan without supporting evidence either in adults or
children
Name ATCa Therapeutic use Adult efficacyb Paediatric efficacyb Dosage Formc
Paromomycin A Leishmaniasis No evidence No evidence NA
Linezolid J Tuberculosis No evidence No evidence A
Morphine N Sedationd No evidence No evidence A
Amodiaquine P Malaria No evidence No evidence NA
Artemether P Malaria Inconclusive Inconclusive NA
Nifurtimox P African trypanosomiasis Inconclusive No evidence NA
Nifurtimox P American trypanosomiasis Inconclusive No evidence NA
Levamisole P Helminth infection Inconclusive No evidence NA
Benzyl benzoate P Scabies No evidence No evidence NA
aAnatomical Therapeutic Chemical (ATC) classification code: A, alimentary tract and metabolism; J, general anti-infectives for systemic use; N, nervous system; P,
antiparasitic products
bAdult or paediatric efficacy: Inconclusive, evidence is inconclusive
cDosage Form: A, available; NA, not available
dMorphine is listed in the EMLc as the drug of choice for the treatment of severe acute or chronic pain, which was acknowledged as approved in the three
countries. However, efficacy of morphine for sedation has not been established or approved in any of the three countries. That is why the listing of morphine
indicated to sedation as unapproved
Table 9 Essential medicines for children unapproved in the US, UK, and Japan without a paediatric dosage form
Name ATCa Therapeutic use Adult efficacyb Paediatric efficacyb
Paromomycin A Leishmaniasis No evidence No evidence
Diphtheria antitoxin J Diphtheria Effective Effective
Amodiaquine P Malaria No evidence No evidence
Artemether P Malaria Inconclusive Inconclusive
Artesunate P Malaria Effective Effective
Artesunate + Mefloquine P Malaria Effective Effective
Artesunate + Amodiaquine P Malaria Effective Effective
Benznidazole P American trypanosomiasis Inconclusive Favours efficacy
Sodium stibogluconate P Leishmaniasis Favours efficacy No evidence
Nifurtimox P African trypanosomiasis Inconclusive No evidence
Nifurtimox P American trypanosomiasis Inconclusive No evidence
Melarsoprol P African trypanosomiasis Favours efficacy No evidence
Suramin sodium P African trypanosomiasis Favours efficacy No evidence
Eflornithine P African trypanosomiasis Effective No evidence
Triclabendazole P Infection by Paragonimus Favours efficacy Inconclusive
Levamisole P Helminth infection Inconclusive No evidence
Benzyl benzoate P Scabies No evidence No evidence
aAnatomical Therapeutic Chemical (ATC) classification code: A, alimentary tract and metabolism; J, general anti-infectives for systemic use; P, antiparasitic products
b Adult or paediatric efficacy: Inconclusive, evidence is inconclusive; Favours efficacy, evidence favours efficacy
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extrapolating prior knowledge acquired during the de-
velopment of these medicines for adults, on the basis of
assuming a similar disease for the proposed paediatric
indication [31, 32]. The remaining nine of the 26 un-
approved medicines have no evidence in either adults or
children. Eight of these nine, excluding morphine for
sedation, are antiparasitic or anti-infective products indi-
cated for NIDs.
The distribution of EMLc medicines according to thera-
peutic area shows that the EMLc addresses the most
pressing public health concerns of children around the
world, namely, NIDs [13]. Our study showed that 26 of
the 39 medicines unapproved in all three countries were
indicated for NIDs. Whereas all of the antiretrovirals listed
on the EMLc were approved in one or more of the three
countries assessed, we found that 40% of antiparasitics
were unapproved in all three countries despite their public
health relevance in LMICs. This distinction highlights the
interest of HICs regarding infectious diseases that are
prevalent in their own countries but not in LMICs.
Pharmaceutical companies, in association with re-
searchers, are the key stakeholders in paediatric develop-
ment. Incentives are imperative for them to develop
medicines for NIDs [33, 34] because the market potential
is quite low and external funding has been reduced [35].
A combination of push and pull incentive mechanisms
[34] has been proposed as being suitable to promote clin-
ical development for NIDs. Push mechanisms, such as re-
search grants or publicly financed institutions, support
basic research whereas pull mechanisms, such as priority
review vouchers or extension of the medicine’s exclusivity
period [33], have the potential to stimulate research and
development of medicines for NIDs. Because of the lim-
ited resources in LMICs, these incentives should be
applied to paediatric development for NIDs of high prior-
ity, which are the WHO roadmap targets for eradication
and elimination [36].
Several limitations of this analysis should be noted.
First, we used DRUGDEX as the only source, to clas-
sify supporting evidence of efficacy. Whereas this
database is well recognised and is easily available, it is
compiled by an expert working group in an HIC,
namely, the US. By defining the presence or absence
of supporting evidence according to DRUGDEX, the
evidence we identified as “no evidence” may include
varying degrees of scientific evidence that fell short of
our definition. This limitation would be particularly
applicable to medicines for NIDs. Second, because we
had to rely on data collected for different purposes by
other groups, we were limited in our ability to capture
the gradient of evidence for EMLc medicines. Third,
we could not address social obstacles to accessing
EMLc medicines such as cost, intellectual property, or
logistics, because we focused on the scientific aspects
of the EMLc. Finally, we were limited to collecting ap-
proval data from the US, UK, and Japan and omitted
approvals and development outside these regions.
Conclusion
HICs have made a substantial contribution to improve
the scientific evidence and availability of paediatric dos-
age forms for EMLc in some therapeutic areas, such as
antiretrovirals and antineoplastics. To date, however,
there has been little commitment of HICs to NIDs
given their large economies. Deficiencies in the ability
to meet the critical needs of children worldwide re-
main, particularly with respect to NIDs. To make
paediatric development for NIDs feasible and effective,
appropriate incentive mechanisms for pharmaceutical
companies should be applied towards the eradication
and elimination of NIDs.
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